Dab/Tram (dabrafenib and trametinib)

ROAR



Dab/Tram (dabrafenib and trametinib) ROAR	Dab/Tram (dabrafenib and trametinib) ROAR
PRELIMINARY SCORE	SCORE
CURATIVE	CURATIVE
	Overall Survival / Disease-Free Survival / Pathological Complete Response
NON-CURATIVE	NON-CURATIVE
ORR	NON-CONATIVE
ADJUSTMENTS	Overall Survival
Quality of life	
	Progression-Free Survival
Not qualified for an ESMO-MCBS credit	
Continue and disability and consent office to	Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate
Serious and disabling adverse effects	3
	Overall Response Rate / Duration of Response
	Overall Survival / Disease-Free Survival / Pathological Complete Response
Other adjustments	INFORMATION
	Tumour type: Brain Tumours Therapeutic Indication: For the treatment of adult and pediatric patients ≥ 6 years of age with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options Experimental Arm: Dab/Tram (dabrafenib and trametinib) Control Arm: Single arm (Phase II)



© 2024 | European Society for Medical Oncology | ESMO - MCBS 1.1 | All rights reserved worldwide.